An economic evaluation of a perindopril-based blood pressure lowering regimen for patients who have suffered a cerebrovascular event

European Journal of Health Economics

Volumn 10, Issue 1, 2009, Pages 111-119

  Tavakoli, Manouchehr ^a   Pumford, Neil ^b   Woodward, Mark ^c   Doney, Alex ^d   Chalmers, John ^e   MacMahon, Stephen ^e   MacWalter, Ronald ^d  

^a UNIVERSITY OF ST ANDREWS   (United Kingdom)

^b Nurseplus Ltd   (United Kingdom)

^c MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF DUNDEE   (United Kingdom)

^e UNIVERSITY OF SYDNEY   (Australia)

Author keywords

Blood pressure lowering; Cerebrovascular; Cost effectiveness; Markov

Indexed keywords

INDAPAMIDE; PERINDOPRIL;

ADULT; AGED; ARTICLE; BARTHEL INDEX; BLOOD PRESSURE REGULATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DRUG COST; FEMALE; HEALTH CARE UTILIZATION; HOSPITALIZATION COST; HUMAN; LENGTH OF STAY; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; RANDOMIZED CONTROLLED TRIAL; RECURRENT DISEASE; RESOURCE ALLOCATION; STROKE; TRANSIENT ISCHEMIC ATTACK;

AGED; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; COST-BENEFIT ANALYSIS; FEMALE; HOSPITAL COSTS; HUMANS; HYPERTENSION; MALE; MARKOV CHAINS; MIDDLE AGED; MONTE CARLO METHOD; PERINDOPRIL; QUALITY-ADJUSTED LIFE YEARS; STROKE;

EID: 58149084017     PISSN: 16187598     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10198-008-0108-3     Document Type: Article

References (53)

1. World Health Organization.: The World Health Report. WHO, Geneva (1999)
2. C. Murray A. Lopez 1997 Mortality by cause for eight regions of to the world: global burden of disease study Lancet. 349 1269 1276
3. Wade D.: Stroke. In: Stevens A., Raftery J. (eds.) Health Care Needs Assessment: The Epidemiologically Based Needs Assessment Reviews. Radcliffe Medical Press, Oxford (1994)
4. G. Hankey C. Warlow 1999 Treatment and secondary prevention of stroke: evidence, costs, and effects on individuals and populations Lancet. 354 1457 1463
5. Department of Health: National Service Framework for Coronary Heart Disease. London (2000)
6. Office for National Statistics: Mortality Statistics - Causes. London (1997)
7. Yuen, P.: OHE Compendium of Health Statistics. Office of Health Economics, London (2004)
8. ISD.: Stroke: Incidence and Mortality (2005)
9. Wolfe, C., Rudd, A., Beech, R.: Stroke Services and Research. An Overview with Recommendations for Future Research. Stroke Association, London (1996)
10. Office of Health Economics: Stroke. Office of Health Economics (1988)
11. P. Chalmers 1999 1999 World Health Organization-International Society of Hypertension Guidelines for the Management of Hypertension Guidelines Subcommittee. Journal of Hypertension. 17 2 151 183
12. Department of Health: National Service Framework for Older People. London (2001)
13. A. Rudd P. Irwin Z. Rutledge D. Lowe D. Wade R. Morris M. Pearson 1999 The national sentinel audit of stroke: a tool for raising standards of care J. R. Coll. Physicians. 30 460 464
14. Guidelines Subcommittee 1999 1999 World health organization-international society of hypertension guidelines for the management of hypertension J. Hypertens. 17 151 183
15. M. Chambers J. Hutton J. Gladman 1999 Cost-effectiveness analysis of antiplatelet therapy in the prevention of recurrent stroke in the UK: aspirin, dipyridamole and aspirin-dipyridamole Pharmacoeconomics. 16 5 pt2 577 593
16. S. Straus S. Majumdar A. Findlay 2002 A new evidence from stroke prevention: scientific review J. Am. Med. Assoc. 288 11 1388 1395
17. H.C. Diener L. Cunha C. Forbes J. Sivenius P. Smets A. Lowenthal 1996 European stroke prevention study, 2: dipyridamole and acetylsalicylic acid in the secondary prevention of stroke J. Neurol. Sci. 143 1 13
18. Antithrombotic Trialists' Collaboration 2002 Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients BMJ. 324 71 86
19. PROGRESS Management Committee 1996 Blood pressure lowering for the secondary prevention of stroke rationale and design for PROGRESS J. Hypertens. 14 Suppl 2 S41 S46
20. S. MacMahon R. Peto J. Cutler R. Collins P. Sorlie J. Neaton R. Abbott J. Godwin A. Dyer J. Stamler 1990 Blood pressure, stroke, and coronary heart disease. Part 1, prolonged differences in blood pressure: prospective observational studies corrected for the regression dilution bias Lancet. 335 765 774
21. Asia Pacific Cohort Studies Collaboration 2003 Blood pressure and cardiovascular diseases in the Asia-Pacific region J. Hypertens. 21 707 716
22. PROGRESS Collaborative Group 2001 Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6,105 individuals with previous stroke or transient ischaemic attack Lancet. 358 9287 1033 1041
23. Heart Outcomes Prevention Evaluation (HOPE) Study Investigators 2000 Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy Lancet. 355 253 259
24. Blood Pressure Lowering Treatment Trialists' Collaboration 2000 Effects of ACE inhibitors, calcium antagonists, and other blood-pressure-lowering drugs: results of prospectively designed overviews of randomised trials Lancet. 356 1955 1964
25. PROGRESS Collaborative Group 2003 Effects of a perindopril-based blood pressure lowering regimen on cardiac outcomes among patients with cerebrovascular disease Eur. Heart. J. 24 475 484
26. F.A. Sonnenberg R.J. Beck 1993 Markov models in medical decision making: a practical guide Med. Decis. Mak. 13 4 322 338
27. R.J. Beck S.G. Pauker 1983 The Markov process in medical prognosis Med Decis. Mak. 3 4 419 458
28. A.J. Nordmann M. Krahn A.G. Logan G. Naglie A.S. Detsky 2003 The cost effectiveness of ACE inhibitors as first-line antihypertensive therapy Pharmacoeconomics. 21 8 573 585
29. E.L. Eisenstein E.D. Peterson J.G. Jollis B.E. Tardiff R.M. Califf J.D. Knight D.B. Mark 2000 Evaluating the potential 'economic attractiveness' of new therapies in patients with Non-ST elevation acute coronary syndrome Pharmacoeconomics. 17 3 263 272
30. Kuntz, K., Weinstein, M.: Modelling in economic evaluation. In: Drummond, M., McGuire, A. (eds.) Economic Evaluation in Health Care: Merging Theory with Practice. pp. 141-171. OUP, Oxford (2001)
31. C. Collin D. Wade S. Davies V. Horne 1988 The Barthel ADL index: a reliability study Int. Disabil. Stud. 10 2 61 63
32. J.J. Caro K.F. Huybrechts H.E. Kelley 2001 Predicting treatment costs after acute ischemic stroke on the basis of patient characteristics at presentation and early dysfunction Stroke. 32 100 106
33. J.L. Wolstenholme P. Fenn A.M. Gray J. Keene R. Jacoby T. Hope 2002 Estimating the relationship between disease progression and cost of care in dementia Br. J. Psychiatry. 181 36 42
34. N. Chapman R. Huxley C. Andersion M.G. Bousser J. Chalmers S. Colman S. Davis G. Donnan S. MacMahon B. Neal C. Warlow M. Woodward 2004 Effects of perindopril-based blood pressure lowering regimen on the risk of recurrent stroke according to stroke subtype and medical history: the PROGRESS trial Stroke. 35 116 121
35. D. Johnson 2002 Triangular approximations for continuous random variables in risk analysis J Oper Res Soc. 53 457 467
36. K. Hardie K. Jamrozik G.J. Hankey R.J. Broadhurst C. Anderson 2005 Trends in five-year survival and risk of recurrent stroke after first-ever stroke in the Perth Community Stroke Study Cerebrovasc. Dis. 19 179 185
37. A. Terént 2004 Cerebrovascular mortality 10 years after stroke a population-based study Stroke. 35 e343 e345
38. K. Hardie G.J. Hankey K. Jamrozik R.J. Broadhurst C. Anderson 2003 Ten-year survival after first-ever stroke in the Perth Community Stroke Study Stroke. 34 1842 1846
39. H. Brønnum Hansen M. Davidsen P. Thorvaldsen 2001 Long-term survival and causes of death after stroke Stroke. 32 2131 2136
40. C. Marini R. Totaro A. Carolei 1999 Long-term prognosis of cerebral ischemia in young adults Stroke. 30 2320 2325
41. R. MacWalter D. Coid H. Fraser Y. Ersoy 1999 The Dundee Stroke Register: experience of the first ten years Scott. Med. J. 44 4 103 105
42. Office for National Statistics: Mortality statistics general review of the registrar general on deaths in England and Wales, 2002 Series DH1 no.35. London. 72, Table 8 (2004)
43. S. Simoens 2006 Using the Delphi technique in economic evaluation: time to revisit the oracle? J. Clin. Pharm. Ther. 31 6 519 522
44. Scottish Health Statistics: Scottish health service costs NHS national services Scotland, (2004)
45. British National Formulary: BMJ Publishing Group Ltd and Royal Pharmaceutical Society of Great Britain, No. 50, (2005)
46. H.S. Jørgensen H. Nakayama H.O. Raaschou T.S. Olsen 1997 Acute stroke care and rehabilitation: an analysis of the direct cost and its clinical and social determinants: the Copenhagen stroke study Stroke. 28 1138 1141
47. A.H. Briggs 2000 Handling uncertainty in cost-effectiveness models Pharmacoeconomics. 17 5 479 500
48. Johnson, D.: The triangular distribution as a proxy for the beta distribution in risk analysis. Statistician. 46(3), 387-398 (1997)
49. National Institute for Clinical Excellence: Guide to the methods of technology appraisal April 2004 (2004)
50. National Institute for Health and Clinical Excellence: Social value judgement-principles for the development of NICE guidance, December (2005). http://www.nice.org.uk/page.aspx?o=283494
51. B. Jonsson M. Johannesson J. Kjekshus A. Olsson T. Pedersen H. Wedel 1996 Cost-effectiveness of cholesterol lowering. Results from the scandinavian simvastatin survival study (4S) Eur. Heart. J. 17 1001 1007
52. P. Youman K. Wilson F. Harraf L. Kalra 2003 The economic burden of stroke in the United Kingdom Pharmacoeconomics. 21 Suppl 1 43 50
53. PROGRESS Collaborative Group. perindopril-based blood pressure lowering in individuals with cerebrovascular disease 2004 Consistency of benefits by age, sex and geographic region J. Hypertens. 22 653 659